Compounding pharmacies in Illinois

By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified Sep 22, 2026

The Illinois State Board of Pharmacy (Illinois Department of Financial and Professional Regulation) regulates compounding pharmacies in Illinois. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Illinois at a glance

Pharmacy regulator: Illinois State Board of Pharmacy (Illinois Department of Financial and Professional Regulation)
503A framework: Follows the federal 503A framework
Telehealth prescribing: Regulatory: Telehealth allowed
Asynchronous prescribing: Regulatory: Async unclear
Compounded GLP-1 access: Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Illinois

No verified compounding pharmacies serving Illinois are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Illinois

In Illinois, pharmacy licensing and discipline are handled by the Department of Financial and Professional Regulation (IDFPR) with the State Board of Pharmacy acting in an advisory role, under the Pharmacy Practice Act (225 ILCS 85) and the rules at 68 Illinois Administrative Code Part 1330. Illinois has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Under 225 ILCS 85/16a, a nonresident pharmacy (one outside Illinois that ships, delivers, dispenses, or distributes prescription drugs into Illinois by any means, including over the internet) must be licensed by IDFPR and follow the Department's nonresident rules. Section 1330.640 (Pharmaceutical Compounding Standards) governs both sterile and nonsterile compounding by the official USP-NF (USP 47-NF 42, 2024 edition), limits dispensing of compounded drugs to valid patient-specific prescriptions except for defined nonsterile office use, and prohibits sterile compounding for office use unless the pharmacy is registered as a 503B outsourcing facility and licensed as a wholesale distributor; the former separate sterile section, 1330.670, is repealed. Section 1330.30(j) lists as unprofessional conduct dispensing or offering to dispense any drug that is not FDA approved, not in the USP-NF, and not on the FDA list of bulk drug substances that may be used in compounding. [1] [3] [4] [7]

Compounded GLP-1 access in Illinois

Illinois patients using telehealth GLP-1 programs should confirm the prescriber holds an Illinois license and that the dispensing pharmacy holds an IDFPR nonresident pharmacy license. IDFPR has not issued its own GLP-1 rule, but it relays federal positions to licensees: its Pharmacy page posts FDA's July 2024 letter on adverse events with compounded semaglutide and tirzepatide, and its Spring 2025 compliance newsletter restated FDA's timelines that ended 503A enforcement discretion for compounded tirzepatide and set April 22, 2025 for semaglutide. [1] [2] [3] [6] [10]

Research use only sellers in Illinois

Only IDFPR-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Illinois patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. The Illinois Food, Drug and Cosmetic Act, 410 ILCS 620/17, separately bars any person from selling, delivering, holding for sale, or giving away a new drug unless an application for it has been approved under section 505 of the federal act, and 68 Ill. Adm. Code 1330.30(j) makes dispensing a drug that is not FDA approved, not in the USP-NF, and not on the FDA bulks list unprofessional conduct for a licensee. [3] [4] [5] [11]

Illinois notes on specific peptides

Semaglutide: Available branded by prescription from an Illinois-licensed provider, including by telehealth under 225 ILCS 150. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [2] [10]

How to check a compounding pharmacy in Illinois

Search the Illinois State Board of Pharmacy (Illinois Department of Financial and Professional Regulation) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Illinois requires before it ships to you. [1] [3] [4] [7]
Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Illinois. [3] [4] [5] [11]

Common questions in Illinois

What does an out-of-state pharmacy need to ship compounded peptides to Illinois?

A nonresident pharmacy license from the Illinois Department of Financial and Professional Regulation under 225 ILCS 85/16a, which covers pharmacies that ship or deliver prescription drugs into Illinois by any means, including online. Check the IDFPR license lookup before ordering. [1] [3]

Can an Illinois pharmacy compound BPC-157?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [8] [9]

All peptide legal questions for Illinois